Industry News

OpGen, Inc., an informatics and genomic analysis company, announces the completion of its multi-drug resistant organisms health outcomes study with Intermountain Healthcare. It was a collaboration between Intermountain Healthcare and Enterprise Analysis Corporation in a retrospective study to explore multi-drug resistant organisms and Clostridium difficile trends throughout the Intermountain Healthcare System over an 8- year period."/>
OpGen Announces Completion of the Intermountain Healthcare Retrospective MDRO Health Outcome Study
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, today announced that it has successfully completed a key preclinical milestone in its collaboration with Astellas Pharma Inc.. The milestone, which triggered an undisclosed payment from Astellas, demonstrated that selective modulation of the Unfolded Protein..."/>
Proteostasis Therapeutics Achieves Preclinical Milestone in Astellas Pharma Collaboration
Exact Sciences Corp. today announced that the company will participate in the Canaccord Genuity 36th Annual Growth Conference. Kevin Conroy, the company's chairman and chief executive, will participate in a fireside chat on Wednesday, Aug. 10 at 10:30 a.m. ET. A live webcast of the fireside chat will be available through the company's website at www.exactsciences.com."/>
Exact Sciences to participate in Canaccord Genuity 36th Annual Growth Conference
Proteostasis Therapeutics, Inc., a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the appointment of James M. DeTore as chief financial officer, Geoffrey S. Gilmartin, M.D. as chief development officer, Marija Zecevic, Ph.D. as vice president of business development, and Eric B. Rabinowitz as a new member of the company’ s board of..."/>
Proteostasis Therapeutics Announces Key Leadership Appointments
Canopy Growth Corporation is pleased to announce that, due to strong demand, it has agreed with a syndicate of underwriters led by GMP Securities L.P. and Dundee Securities Ltd., and including INFOR Financial Inc. and PI Financial Corp., to increase the size of its previously announced $25,000,000 bought..."/>
Canopy Growth Corporation Announces Increase to Bought Deal Financing
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Carl Spana, the Company's President& Chief Executive Officer, will present at the 36 th Annual Canaccord Genuity Growth Conference on Thursday, August 11 th, 2016 at 1:00 p.m. Eastern time."/>
Palatin Technologies to Present at the 36th Annual Canaccord Genuity Growth Conference
Varian Medical Systems. Housing two treatment rooms offering image-guided intensity-modulated proton therapy, as well as one room dedicated to research, clinicians at the center are now working with patients and planning to begin treatments in September. The center will also utilize the ARIA ® Oncology..."/>
Cincinnati Children's/UC Health Proton Therapy Center Opens with ProBeam System from Varian
Amadeus invests in genetic testing pioneers, Igenomix
MEI Pharma is to get $20 million in near-term cash and potentially hundreds millions more under a cancer drug partnership with Helsinn Group. The deal licenses MEI Pharma's Pracinostat to the Swiss drug company under an exclusive worldwide agreement to develop and commercialize the drug for acute myeloid leukemia and possibly other conditions. Pracinostat has finished a Phase 2 trial for acute myeloid leukemia and is ready for Phase 3 trials, said Daniel..."/>
MEI Pharma lands major deal for cancer drug Pracinostat [The San Diego Union-Tribune]
Wockhardt Ltd plunged almost 10% on Monday after the US Food and Drug Administration on the weekend banned imports from the drug maker's plant in Ankleshwar, Gujarat. In its order on Friday, FDA cited non-compliance with current good manufacturing practices in slapping the ban on the active pharmaceutical ingredients plant. Wockhardt shares ended trading down 9.88% to Rs.915.30 on Monday after having fallen as much as 14% in early trading."/>
Wockhardt shares plunge on US import ban [Mint, New Delhi]
Mettrum Health Corp.,, a vertically integrated provider of cannabis products, is pleased to announce that further to its press release on August 8, 2016, the Company and Cormark Securities Inc., on behalf of a syndicate of underwriters including Mackie Research Capital Corporation, GMP Securities L.P., Clarus Securities Inc., Dundee Securities Ltd., Echelon Wealth Partners Inc. and PI..."/>
Mettrum Announces Increase to Bought Deal Financing
Amarantus BioScience Holdings, Inc., a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16- subject clinical study of Engineered Skin Substitute in children with life-threatening severe burns. In this study, ESS was compared with the standard of care for treating full-thickness life-threatening pediatric severe burns covering a..."/>
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET. To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com. GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell..."/>
GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference
SCYNEXIS, Inc., a pharmaceutical company developing novel anti-infectives, today reported financial results for the quarter ended June 30, 2016, and provided an update on recent operational and clinical developments."/>
SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
K2M Group Holdings, Inc. today announced the pricing of a private offering of $50 million aggregate principal amount of 4.125% Convertible Senior Notes due 2036, to be sold only to qualified institutional buyers pursuant to Rule 144 A under the Securities Act of 1933, as amended. The offering is expected to close on August 11, 2016, subject to customary closing conditions.. The Notes will pay interest semi-annually in cash on February 15 and August 15 at a..."/>
K2M Group Holdings, Inc. Announces Pricing of Private Offering of $50 Million Aggregate Principal Amount of 4.125% Convertible Senior Notes due 2036
Helius Medical Technologies, Inc. a company focused on the treatment of neurological symptoms caused by disease or trauma, announced today that Thomas Griffin will join the Board of Directors, effective immediately. Griffin will also serve as Chairman of the Audit Committee. Tom is currently Vice President of Finance for Entellus Medical, Inc., a medical technology company focused on delivering superior patient and physician experiences..."/>
Helius Medical Technologies Appoints Thomas Griffin to Board of Directors and Chairman of the Audit Committee
Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity 36 th Annual Growth Conference. Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help..."/>
Vermillion to Present Corporate Overview at the Canaccord Genuity 36th Annual Growth Conference
Halyard Health and Team Gleason today announced they are teaming up to raise awareness for amyotrophic lateral sclerosis, commonly known as ALS, a terminal neuromuscular disease. Team Gleason, a nonprofit organization that provides leading-edge technology, equipment and services to individuals with neuromuscular diseases or injuries, was founded by former professional football player Steve Gleason and his wife..."/>
Halyard Health and Team Gleason Team Up for ALS Awareness
Sorrento Therapeutics, Inc., has entered into a binding term sheet to acquire SCILEX Pharmaceuticals, Inc.. Scintilla's lead program is resiniferatoxin for the treatment of intractable cancer pain. SCILEX, based in Malvern, PA, is engaged in the development and commercialization of products focused on the treatment of pain."/>
Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business
Verastem, Inc., focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate developments. “We continue to execute on the research and development of our two clinical-stage oncology programs targeting several high unmet need tumor types,” said Robert Forrester, President and Chief Executive Officer of Verastem.“ The scientific evidence of the..."/>
Verastem Reports Second Quarter 2016 Financial Results
Coherus BioSciences, Inc., today reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab biosimilar candidate. This study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index at Week 12. The 95% confidence intervals for the difference between treatment groups fell well within the..."/>
Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis
ViewRay, Inc., makers of the world's first and only clinical MRI-guided radiation therapy system, announced today highlights from the recent 2016 Annual Meeting of the American Association of Physicists in Medicine, which featured extensive clinical experience with the company's MRIdian System, including the first data from the company's MRIdian linear accelerator technology, which is currently under development."/>
First Scientific Presentations on ViewRay's MRIdian Linac Technology

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary609 Articles
Information Technology558 Articles
Financials495 Articles
Industrials365 Articles
Health Care313 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.